Silverback Therapeutics also developed the ImmunoTAC platform and designed several ISACs using TLR8 agonists as payloads, such as SBT6050, SBT6290, and SBT8230.84 As for STING, it is also a well-studied innate immune pathway and STING agonist are capable of inducing anti-tumor immune activity.85 CRD5500 from Takeda and XMT-2056 from Mersana are two leading STING-agonist ADC programs under the clinical development.86,87 ISACs is a relatively new area but some candidates have successively entered clinical development, and their follow-up progress is expected.78,88,89. This evidence concerns the gene STING1 and neoplasm.